Over the past decade, there has been significant advancement in the understanding of the
pathophysiology of melanoma. These advancements have led to the systematic …

The remarkable advances in the systemic therapy of metastatic melanoma have now
extended the 1-year overall survival rate from 25% to nearing 85%. Systemic treatment in …

Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

Purpose To assess the predictive value of the tumor staging system in the AJCC Cancer
Staging Manual, Eighth Edition, and histologic features for outcomes and metastasis …

Opinion statement Melanoma has a high propensity to metastasize to the brain which
portends a poorer prognosis. With advanced radiation techniques and targeted therapies …

Brain metastases (BM) from cutaneous melanoma are associated with poor prognosis.
Population-based data describing the associated factors of incidence and prognosis of BM …

Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …

Real-world evidence plays an important role in the assessment of efficacy and safety of
novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with …

Simple Summary The treatment strategies of patients with melanoma brain metastases are
continually evolving, although this remains a poor prognostic subset. We report a real-life …

Primary tumours, particularly from major solid organs, are able to disseminate into the blood
and lymphatic system and spread to distant sites. These secondary metastases to other …